Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants
Open accessAbstract
Abstract N,N-dimethyltryptamine (DMT) is distinct among classic serotonergic psychedelics because of its short-lasting effects when administered intravenously. Despite growing interest in the experimental and therapeutic use of intravenous DMT, data are lacking on its clinical pharmacology. We conducted a double-blind, randomized, placebo-controlled crossover trial in 27 healthy participants to test different intravenous DMT administration regimens: placebo, low infusion (0.6 mg/min), high infusion (1 mg/min), low bolus + low infusion (15 mg + 0.6 mg/min), and high bolus + high infusion (25 mg + 1 mg/min). Study sessions lasted for 5 h and were separated by at least 1 week. Participant’s lifetime use of psychedelics was ≤20 times. Outcome measures included subjective, autonomic, and adverse effects, pharmacokinetics of DMT, and plasma levels of brain-derived neurotropic factor (BDNF) and oxytocin. Low (15 mg) and high (25 mg) DMT bolus doses rapidly induced very intense psychedelic effects that peaked within 2 min. DMT infusions (0.6 or 1 mg/min) without a bolus induced slowly increasing and dose-dependent psychedelic effects that reached plateaus after 30 min. Both bolus doses produced more negative subjective effects and anxiety than infusions. After stopping the infusion, all drug effects rapidly decreased and completely subsided within 15 min, consistent with a short early plasma elimination half-life (t1/2α) of 5.0–5.8 min, followed by longer late elimination (t1/2β = 14–16 min) after 15–20 min. Subjective effects of DMT were stable from 30 to 90 min, despite further increasing plasma concentrations, thus indicating acute tolerance to continuous DMT administration. Intravenous DMT, particularly when administered as an infusion, is a promising tool for the controlled induction of a psychedelic state that can be tailored to the specific needs of patients and therapeutic sessions. Trial registration: ClinicalTrials.gov identifier: NCT04353024
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The study excluded participants with more than 15 lifetime psychedelic experiences, resulting in a sample with no or only little previous psychedelic experience.
“While other studies investigating psychedelics often include participants with previous psychedelic experience (17, 18), we excluded participants more than 15 lifetime psychedelic experiences resulting in a sample with no or only little previous psychedelic experience.”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [18]
The Methods and Materials > Participants passage gives an exclusion threshold of more than 20 lifetime uses of hallucinogenic substances, not more than 15. It also reports that 24 of 27 participants had previously used a psychedelic, although their reported use of individual psychedelics was limited. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredWhile the intensity of the experience was rather moderate-as expected with the incremental dosing of 10 single doses à 10 mg of DMT-the study set up, including the experimental tasks, might have even attenuated the subjective effects and distracted participants from their inner processes.
“While the intensity of the experience was rather moderate–as expected with the incremental dosing of 10 single doses à 10 mg of DMT [compare also bolus and total doses of other studies, e.g., (18)]–the study set up, including the experimental tasks, might have even attenuated the subjective effects and distracted participants from their inner processes, as reported in some of the diary texts (ex”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · see citing works
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · cited 1× · see citing works
“Moreover, in vitro and animal studies demonstrated the neuroplasticity-promoting properties of psychedelics, including DMT [28].”
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · cited 1× · see citing works
“The 5 Dimensions of Altered States of Consciousness (5D-ASC) scale [30, 31] was used as the primary outcome measure and was administered 150 min after drug administration to retrospectively rate peak drug effects.”
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637 · see citing works
The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans
Dittrich, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979351 · Cited by 577 · cited 1× · see citing works
“The 5 Dimensions of Altered States of Consciousness (5D-ASC) scale [30, 31] was used as the primary outcome measure and was administered 150 min after drug administration to retrospectively rate peak drug effects.”
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453 · see citing works
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 409 · see citing works
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379 · see citing works
Neural correlates of the DMT experience assessed with multivariate EEG
Timmermann, C., Roseman, L., Schartner, M., Milliere, R., Williams, L. T. J., Erritzoe, D., Muthukumaraswamy, S., Ashton, M., Bendrioua, A., Kaur, O., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51974-4 · Cited by 315 · cited 2× · see citing works
“Thus, a psychedelic experience can be tailored to the speci fi c needs of patients and therapeutic settings.”
InfluentialDose-Response Study of N,N-Dimethyltryptamine in Humans
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020009001 · Cited by 291 · see citing works
Human psychopharmacology of N,N-dimethyltryptamine
Strassman, R. J. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00081-2 · Cited by 261 · see citing works
Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00883-6 · Cited by 245 · cited 3× · see citing works
“Thus, a psychedelic experience can be tailored to the speci fi c needs of patients and therapeutic settings.”
Ayahuasca: pharmacology, neuroscience and therapeutic potential
Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., Friedlander, P., Feilding, A., & Riba, J. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.002 · Cited by 226 · cited 1× · see citing works
“INTRODUCTION N,N -dimethyltryptamine (DMT) is a naturally occurring psychedelic that is a component of Ayahuasca, which is widely used for recreational and spiritual purposes [1].”
Holze, F., Ley, L., Müller, F., Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A., Duthaler, U., Kolaczynska, K. E., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01297-2 · Cited by 226 · cited 2× · see citing works
“Thus, a psychedelic experience can be tailored to the speci fi c needs of patients and therapeutic settings.”
Self-citationDMT Models the Near-Death Experience
Timmermann, C., Roseman, L., Williams, L., Erritzøe, D., Martial, C., Cassol, H., Laureys, S., Nutt, D., & Carhart-Harris, R. L. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01424 · Cited by 225 · cited 2× · see citing works
“Thus, a psychedelic experience can be tailored to the speci fi c needs of patients and therapeutic settings.”
InfluentialAlterations of consciousness and mystical-type experiences after acute LSD in humans
Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4453-0 · Cited by 198 · see citing works
Self-citationGouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., & Kovar, K. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-916185 · Cited by 194 · cited 2× · see citing works
“Several studies have investigated the acute effects of DMT alone when administered intravenously [3 – 10], intramuscularly [11 – 14], and by inhalation [2].”
InfluentialBecker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2487 · Cited by 184 · see citing works
Almeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177 · see citing works
D’Souza, D. C., Syed, S. A., Flynn, L. T., Safi-Aghdam, H., Cozzi, N. V., & Ranganathan, M. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01344-y · Cited by 162 · see citing works
Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Varghese, N., Eckert, A., Feilding, A., Ramaekers, J. G., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00099 · Cited by 131 · cited 2× · see citing works
“Thus, a psychedelic experience can be tailored to the speci fi c needs of patients and therapeutic settings.”
Strassman, R. J., Qualls, C. R., & Berg, L. M. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00200-6 · Cited by 130 · cited 2× · see citing works
“Intravenous DMT administration was subsequently investigated in the 1990s [6, 8, 9].”
Becker, A., Klaiber, A., Holze, F., Istampoulouoglou, I., Duthaler, U., Varghese, N., Eckert, A., & Liechti, M. E. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac075 · Cited by 104 · see citing works
Jordi Riba, A., McIlhenny, E. H., Bouso, J. C., & Barker, S. A. (2014) · Drug Testing and Analysis · doi:10.1002/dta.1685 · Cited by 98 · see citing works
Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
Holze, F., Duthaler, U., Vizeli, P., Müller, F., Borgwardt, S., & Liechti, M. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13918 · Cited by 73 · see citing works
Kaplan, J., MANDEL, L. R., Stillman, R. C., Walker, R. W., VandenHeuvel, W. J. A., Gillin, J. C., & Wyatt, R. J. (1974) · Psychopharmacology · doi:10.1007/bf00421376 · Cited by 70 · see citing works
The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide
Rosenberg, D. E., Isbell, H., Miner, E. J., & Logan, C. R. (1964) · Psychopharmacology · doi:10.1007/bf00413244 · Cited by 61 · cited 1× · see citing works
“Several studies have investigated the acute effects of DMT alone when administered intravenously [3 – 10], intramuscularly [11 – 14], and by inhalation [2].”
Gallimore, A. R., & Strassman, R. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00211 · Cited by 53 · see citing works
CLINICAL EVALUATION OF SOME HALLUCINOGENIC TRYPTAMINE DERIVATIVES
Faillace, L. A., Vourlekis, A., & Szára, S. (1967) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196710000-00005 · Cited by 43 · see citing works
Dimethyltryptamine Experiments with Psychotics
Böszörményi, Z., & Szára, S. (1958) · Journal of Mental Science · doi:10.1192/bjp.104.435.445 · Cited by 39 · cited 1× · see citing works
“The fi rst studies with DMT or similar chemical analogs began in the 1950s, which used intramuscular administration to mimic psychotic states in healthy volunteers and patients [12, 13, 15 – 17].”
Psychological Effects and Metabolism of N,N-diethyltryptamine in Man
Szára, S. (1966) · Archives of General Psychiatry · doi:10.1001/archpsyc.1966.01730150096014 · Cited by 33 · see citing works
Luethi, D., Kolaczynska, K. E., Vogt, S. B., Ley, L., Erne, L., Liechti, M. E., & Duthaler, U. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123534 · Cited by 27 · see citing works
Eckernäs, E., Timmermann, C., Carhart-Harris, R. L., Röshammar, D., & Ashton, M. (2022) · Clinical and Translational Science · doi:10.1111/cts.13410 · Cited by 24 · see citing works
Szara, S. I. (2007) · PubMed · Cited by 22 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [17]Szara S. The comparison of the psychotic effect of tryptamine derivatives with the effects of mescaline and LSD-25 in self-experiments. In: Garattini S, Ghetti V, editors. Psychotropic Drugs. Amsterdam: Elsevier; 1957.
Cited by
Sorted by citations
Yao, Y., Guo, D., Lu, T., Liu, F.-L., Huang, S., Diao, M.-Q., Li, S., Zhang, X.-J., Kosten, T. R., Shi, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115886 · Cited by 149 · see citing works
Cardiovascular safety of psychedelic medicine: current status and future directions
Wsół, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00539-4 · Cited by 60 · see citing works
In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin
Thomann, J., Kolaczynska, K. E., Stoeckmann, O. V., Rudin, D., Vizeli, P., Hoener, M. C., Pryce, C. R., Vollenweider, F. X., Liechti, M. E., & Duthaler, U. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1391689 · Cited by 59 · see citing works
Holze, F., Singh, N., Liechti, M., & D'Souza, D. (2024) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.01.007 · Cited by 44 · see citing works
Exploring DMT: Endogenous role and therapeutic potential
Schimmelpfennig, J., & Jankowiak-Siuda, K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110314 · Cited by 54 · see citing works
Effects of DMT on mental health outcomes in healthy volunteers
Timmermann, C., Zeifman, R. J., Erritzøe, D., Nutt, D., & Carhart-Harris, R. L. (2024) · Scientific Reports · doi:10.1038/s41598-024-53363-y · Cited by 44 · see citing works
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Tagen, M., Mantuani, D., van Heerden, L., Holstein, A., Klumpers, L. E., & Knowles, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190865 · Cited by 41 · see citing works
Rucker, J., Roberts, C., Seynaeve, M., Young, A. H., Suttle, B., Yamamoto, T., Ermakova, A. O., Dunbar, F., & Wiegand, F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241246857 · Cited by 41 · see citing works
“This is in line with literature reports of other short-lasting psychedelics, for example, trials with dimethyltryptamine in healthy volunteers (Vogt et al., 2023).”
ResultAicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1302559 · Cited by 33 · see citing works
Egger, K., Aicher, H., Cumming, P. D., & Scheidegger, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05353-6 · Cited by 36 · see citing works
“The Basel study showed dose-dependent increases in heart rate up to 119 BPM and blood pressure up to 159/98 mmHg [7], peaking shortly after the bolus administration and stabilizing within 10–15 min.”
BackgroundMethodResultInfluentialA Brief Historical Overview of Psychedelic Research
Geyer, M. A. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.11.003 · Cited by 33 · see citing works
Dornbierer, D. A., Marten, L., Mueller, J., Aicher, H. D., Mueller, M. J., Boxler, M., Kometer, M., Kosanic, D., von Rotz, R., Puchkov, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1246892 · Cited by 32 · see citing works
“…small dose increments, the 15-min intervals between administrations, and the very short plasma elimination half-life of DMT, approximately 5 – 10 min (Vogt et al., 2023), it seems rather unlikely that this dosing regimen would have produced substantial DMT effects in the absence of MAO inhibition.”
BackgroundBenefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 32 · see citing works
Falchi-Carvalho, M., Wießner, I., Silva, S. R. B., Maia, L. O., Barros, H., Laborde, S., Arichelle, F., Tullman, S., Silva-Costa, N., Assunção, A., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.12.006 · Cited by 28 · see citing works
5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?
Dourron, H. M., Nichols, C. D., Simonsson, O., Bradley, M. K., Carhart-Harris, R. L., & Hendricks, P. S. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06517-1 · Cited by 31 · see citing works
“Overall, it appears that both naturalistic and clinical use of 5-MeO-DMT precipitate reactivations/ flashback-type phenomena at a higher regularity than typical psychedelics, even those with rapid onset, such as DMT (Vogt et al. 2023).”
Shafiee, A., Bahri, R. A., Rafiei, M. A., Abianeh, F. E., Razmara, P., Jafarabady, K., & Amini, M. J. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241234247 · Cited by 23 · see citing works
“…texts were assessed and a total of nine studies were included in this systematic review and meta-analysis (Figure 1) (Becker et al., 2022; de Almeida et al., 2019; Galvão-Coelho et al., 2020; Holze et al., 2021, 2022; Ley et al., 2023; Rocha et al., 2021; de Sousa et al., 2022; Vogt et al., 2023).”
BackgroundRetractedShinozuka, K., Jerotic, K., Mediano, P. A. M., Zhao, A. T., Preller, K. H., Carhart-Harris, R. L., & Kringelbach, M. L. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03187-1 · Cited by 22 · see citing works
“IV administration yields different pharmacokinetics, which are known to in fl uence the subjective experience of the drug [51, 52].”
InfluentialJames, E., Erritzøe, D., Benway, T. A., Joel, Z., Timmermann, C., Good, M., Agnorelli, C., Weiss, B., Barba, T., Campbell, G., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1305796 · Cited by 20 · see citing works
Cardiovascular effects and safety of classic psychedelics
Nahlawi, A., Ptaszek, L. M., & Ruskin, J. N. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00608-2 · Cited by 21 · see citing works
“Acute cardiovascular effects at standard doses are generally limited to mild elevations in heart rate and blood pressure, which are transient and rarely require intervention 64–67 .”
Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278873 · Cited by 20 · see citing works
“However, it is also feasible to obtain measures of psychedelic drug effects in real time using relatively simple measures in the form of visual analog scales (Holze et al., 2022b) or verbal Likert scales (Vogt et al., 2023).”
BackgroundCalder, A. E., Hase, A., & Hasler, G. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02830-z · Cited by 17 · see citing works
Egger, K., Gudmundsen, F., Jessen, N. S., Baun, C., Poetzsch, S. N., Shalgunov, V., Herth, M. M., Quednow, B. B., Martin-Söelch, C., Dornbierer, D., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1140656 · Cited by 17 · see citing works
Erne, L., Vogt, S. B., Müller, L., Nuraj, A., Becker, A., Klaiber, A., Zuparic, M., Varghese, N., Eckert, A., Rudin, D., et al. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-02041-8 · Cited by 16 · see citing works
“The bolus doses produced rapidly increasing subjective effects that were often overwhelming and short-lived [5, 12, 13].”
InfluentialEgger, K., Redondo, J. J., Müller, J., Dornbierer, J., Smallridge, J. W., Aicher, H., Meling, D., Müller, P., Kost, J., Puchkov, M., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117908 · Cited by 14 · see citing works
Erritzøe, D., Barba, T., Benway, T. A., Joel, Z., Good, M., Layzell, M., Baker-Jones, M., Campbell, G., Murphy-Beiner, A., Rands, P., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04154-z · Cited by 13 · see citing works
“Subsequent studies in healthy volunteers have suggested that administering DMT through a slower IV infusion, as opposed to a rapid bolus, may be better tolerated and associated with fewer anxiety-related or adverse subjective effects 10,17,18 .”
Psychedelics, entactogens and psychoplastogens for depression and related disorders
Hoyer, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70088 · Cited by 13 · see citing works
“…et al., 2022; Becker et al., 2022; Holze et al., 2022, 2023; Ley et al., 2023; Müller et al., 2022; Scala et al., 2023; Straumann et al., 2023; Vogt et al., 2023 receptor-dependent or independent is also a matter of debate (Blumenfeld et al., 2024; Cameron, Benatatos, et al., 2023; Casarotto…”
Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives
Czopek, A., Jończyk, J., Fryc, M., Kluzik, D., & Zagórska, A. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00152 · Cited by 12 · see citing works
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
McCulloch, D. E.-W., Liechti, M. E., Kuypers, K. P. C., Nutt, D., Lundberg, J., Stenbæk, D. S., Goodwin, G. M., Gründer, G., Butlen‐Ducuing, F., Haberkamp, M., et al. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.103938 · Cited by 12 · see citing works
“When administered IV, DMT has a short elimination half-life of 5 – 6 min (Vogt et al., 2023).”
Soares, C., Lima, G., Pais, M. L., Teixeira, M., Cabral, C., & Castelo-Branco, M. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1454628 · Cited by 12 · see citing works
“It is known for its intense and relatively short-lived effects on perception, cognition, and mood, including visual imagery and mystical-type experiences (Strassman, 1996; Vogt et al., 2023).”
Chaves, C., SANTOS, R. G. D., Dursun, S. M., Tusconi, M., Carta, M. G., Brietzke, E. M., & Hallak, J. E. C. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1485337 · Cited by 11 · see citing works
Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis
van der Heijden, K. V., Otto, M. E., Schoones, J. W., van Esdonk, M. J., Borghans, L. G. J. M., van Hasselt, J. G. C., van Gerven, J., & Jacobs, G. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01450-8 · Cited by 11 · see citing works
“Intravenous infusion schemes included 30-s bolus [29–32], [34], 90-min infusion [14], [27], 5-min bolus followed by 84-min infusion [26], two consecutive 5-min boluses [15], 30-s bolus followed by 30-min infusion [13] and a 45-s bolus followed by 90-min infusion [14].”
InfluentialMueller, M. J., Aicher, H., Dornbierer, D., Marten, L., Suay, D., Meling, D., Elsner, C., Wicki, I. A., Müller, J., Poetzsch, S. N., et al. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf001 · Cited by 10 · see citing works
Colosimo, F. A., Borsellino, P., Krider, R. I., Márquez, R., & Vida, T. A. (2024) · Psychoactives · doi:10.3390/psychoactives3010007 · Cited by 9 · see citing works
“Curiously, DMT does not increase the levels of BDNF within human participants even at high doses [92].”
BackgroundInfluentialvan der Heijden, K. V., Zuiker, R. G. J. A., Otto, M. E., Bryan, C. F., Stewart, N., Stillwell, C., de Kam, M. L., van Leuken, M. B., van Gerven, J., & Jacobs, G. E. (2025) · Clinical and Translational Science · doi:10.1111/cts.70234 · Cited by 9 · see citing works
“This would support previous studies, where a similar effect was observed following a bolus plus a 30 or 90-min IV infusion [18, 19].”
InfluentialWießner, I., Falchi-Carvalho, M., Laborde, S., Barros, H., Bolcont, R., Silva, S. R. B., Pantrigo, É. J., Medina, M., Arichelle, F., de Almeida, R. N., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.06.002 · Cited by 9 · see citing works
Safety pharmacology of acute mescaline administration in healthy participants
Klaiber, A., Humbert‐Droz, M., Ley, L., Schmid, Y., & Liechti, M. E. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16349 · Cited by 8 · see citing works
Świeczkowski, D., Kwaśny, A., & Cubała, W. J. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111419 · Cited by 8 · see citing works
Pais, M. L., Teixeira, M., Soares, C., Lima, G., Rijo, P. M., Cabral, C., & Castelo-Branco, M. S. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120718 · Cited by 8 · see citing works
“A randomised placebo-controlled study in healthy participants showed that 75 – 79 % of DMT was rapidly cleared from plasma, with an initial half-life of 5, 6 min (Vogt et al., 2023).”
InfluentialAnxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review
Viljoen, G., & Betzler, F. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_534 · Cited by 8 · see citing works
Arikci, D., Holze, F., Mueller, L., Vizeli, P., Rudin, D., Luethi, D., Hysek, C. M., & Liechti, M. E. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3726 · Cited by 7 · see citing works
“41–43 Intravenously administered LSD resulted in higher ratings on the VASs “anxiety,” “bad drug effect,” and “nausea,” higher ratings on the “anxiety” subscale of the 5D-ASC, and higher ratings of “ineffability” on the MEQ30.”
Drewko, A. J., Habets, R. L. P., & Brunt, T. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03169-9 · Cited by 6 · see citing works
“Although some studies reported no such effect [82 – 85], a meta-analysis of 9 trials conducted up to 2023 concludes a signi fi cant difference in plasma BDNF levels between placebo-and psychedelic-treated participants [86].”
Stocker, K., Hartmann, M., Schmid, Y., Vogt, S. B., Becker, A., Ley, L., Straumann, I., Arikci, D., Klaiber, A., Erne, L., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251397328 · Cited by 7 · see citing works
“…were included for the current analysis (Arikci et al., 2025; Becker et al., 2022a, 2022b, 2025; Erne et al., 2024; Holze et al., 2020, 2021, 2022; Klaiber et al., 2024; Ley et al., 2023; Liechti et al., 2017; Schmid et al., 2015; Straumann et al., 2023; Vogt et al., 2023; NCT05523401; NCT05695495).”
N, N -dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an in vitro investigation
Eckernäs, E., Macan-Schönleben, A., Bergström, M. A., Birgersson, S., Hoffmann, K., & Ashton, M. (2023) · Xenobiotica · doi:10.1080/00498254.2023.2278488 · Cited by 6 · see citing works
“After intravenous administration of DMT alone, IAA is the only metabolite that has been measured in any substantial amount, while lesser amounts of DMT N-oxide (DMT-NO) have also been observed (Eckern € as et al. 2022; Luethi et al. 2022; Vogt et al. 2023).”
BackgroundBiological studies of clavine alkaloids targeting CNS receptors
Tasker, N. R., Pazur, E. J., & Wipf, P. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1286941 · Cited by 6 · see citing works
Straumann, I., Vizeli, P., Avedisian, I., Erne, L., Noorshams, D., Vukalović, I., Eckert, A., Luethi, D., Rudin, D., & Liechti, M. E. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02248-3 · Cited by 5 · see citing works
“Speci fi cally, a fast subjective (stimulant or drug-like) effect onset is associated with a higher risk of abuse liability [14 – 16] but may also be linked with negative acute effects, including anxiety [17].”
Rudin, D., Valenta, J., Rolli, H., Liechti, M., & Luethi, D. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112835 · Cited by 5 · see citing works
Pasquini, L., Simon, A. J., Gallen, C. L., Kettner, H., Roseman, L., Gazzaley, A. H., Carhart-Harris, R. L., & Timmermann, C. (2025) · Imaging Neuroscience · doi:10.1162/imag_a_00541 · Cited by 5 · see citing works
“…a serotonergic psy-chedelic ( Nichols, 2016) known to rapidly induce an intense but short-lasting altered state of consciousness ( Strassman, 1995; Vogt et al., 2023), characterized by a sense of transcendence of physical bounds and intense sensory immersion— including vivid and elaborate visual…”
Ley, L., Liechti, M. E., Becker, A., Straumann, I., Klaiber, A., Holze, F., Vogt, S. B., Arikci, D., & Schmid, Y. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06772-4 · Cited by 4 · see citing works
“…years, a multitude of Phase-I trials of a broad range of psychedelic substances have been conducted in our laboratory at University Hospital Basel under similar setting conditions (Holze et al. 2022; Ley et al. 2023; Becker et al. 2023; Vogt et al. 2023; Straumann et al. 2023; Klaiber et al. 2024).”
Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model
Kandilakis, C. L., & Papatheodoropoulos, C. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00892 · Cited by 4 · see citing works
Continuous flow synthesis of N , N -dimethyltryptamine (DMT) analogues with therapeutic potential
Simoens, A., Dejaegere, A., Vandevelde, M., & Stevens, C. V. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00562g · Cited by 4 · see citing works
Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms
Holze, F., Liechti, M. E., & Müller, F. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_510 · Cited by 4 · see citing works
Gomonit, M. M., Swortwood, M. J., Truver, M. T., & Skillman, B. N. (2025) · Journal of Forensic Sciences · doi:10.1111/1556-4029.70013 · Cited by 4 · see citing works
“…randomized, placebo-controlled study testing different intravenous DMT administrations, which collectively reported a very short plasma elimination half-life of 5.0–5.8 minutes for the initial phase, followed by a late elimination half-life of 14–16 min for DMT [ 34 ]. thousands of subjects [ 12 ].”
InfluentialThe psychedelic-peptide paradox: a hormetic hypothesis
Carter, C. S. (2025) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2025.100303 · Cited by 4 · see citing works
Rached, G., Campana, A. M., Fiani, D., Nguyen, C. Y., den Eynde, V. V., Gillman, P. K., & Barnett, B. S. (2026) · CNS Drugs · doi:10.1007/s40263-025-01256-7 · Cited by 3 · see citing works
Roberts, C., Seynaeve, M., Ermakova, A. O., Dunbar, F., Wells, H., Puri, A., Bird, C., & Rucker, J. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261420087 · Cited by 4 · see citing works
“Transient increases in heart rate and blood pressure have also been documented with the acute effects of other psychedelics, such as dimethyltryptamine (Nahlawi et al., 2025; Vogt et al., 2023) and psilocybin (Goodwin et al., 2023).”
How to set up a psychedelic study: Unique considerations for research involving human participants
Glennon, M. J., Bird, C., Yadav, P., Kleine, P., Suseelan, S., Boman-Markaki, C., Kotoula, V., Butler, M., Leech, R., Roseman, L., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106657 · Cited by 5 · see citing works
Registered Clinical Trials of Ayahuasca and DMT : A Scoping Review
Stojanovic, T., Nilsson, K. W., Fredriksson, R., Schiöth, H. B., & Moulin, T. C. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70311 · Cited by 3 · see citing works
Lima, G., Soares, C., Teixeira, M., & Castelo-Branco, M. S. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16264 · Cited by 3 · see citing works
“32,37 When ingested, DMT is inactive primarily due to degradation by MAO-A enzyme.”
Äbelö, A., Smallridge, J. W., von Rotz, R., Dornbierer, D., Egger, K., Ashton, M., & Scheidegger, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118329 · Cited by 3 · see citing works
Higgins, G. A., MacMillan, C., de Lannoy, I., Tyler, C., & Slassi, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251361453 · Cited by 3 · see citing works
“…case of DMT, there is a significant difference between the exposure range in the rat, with clinical exposures of DMT associated with perceptual/psychedelic effects in humans which are more in the 20–60 ng/mL range (Eckernäs et al., 2022; Good et al., 2023; James et al., 2024; Vogt et al., 2023).”
InfluentialCuttler, C., Stueber, A., Simone, J. J., & Mayo, L. M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2452226 · Cited by 3 · see citing works
“When administered alone, the effects of DMT are short-lived (30–45 min), as compared to compounds such as psilo-cybin and LSD, which have enduring effects lasting several hours (Vogt et al. 2023).”
Serotonergic psychedelics for depression: A comprehensive overview
Wingert, A. M., Agnorelli, C., Peill, J., Reed, S., Nutt, D. J., & Erritzoe, D. (2025) · International Review of Neurobiology · doi:10.1016/bs.irn.2025.04.009 · Cited by 2 · see citing works
Not all psychedelics are created equal
Ramaekers, J. G., Mallaroni, P., Mason, N. L., & Avram, M. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00551-y · Cited by 2 · see citing works
Videira, N. B., Nair, V., Paquet, V., & Calhoun, D. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4533 · Cited by 2 · see citing works
“The onset of effects of DMT and 5-MeO-DMT is in the range of seconds to a few minutes when inhaled or smoked or injected IV, and the duration of effects is less than 1 h (Cameron & Olson, 2018; Shen et al., 2010; Vogt et al., 2023).”
BackgroundMarek, G. J., Makai‐Bölöni, S., Umbricht, D., Christian, E. P., Winters, J., Dvořák, D., Raines, S. R., Hughes, Z. A., Austin, E. W., Klein, A. K., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251378512 · Cited by 2 · see citing works
“However, in line with its PK profile, the duration of GM-2505’s cardiovascular effects was shorter than that of psilocybin but longer than that of DMT (Goodwin et al., 2022; Holze et al., 2022; Vogt et al., 2023), demonstrating a more practical temporal profile compared to relatively longer-acting 5-HT 2A receptor ago…”
InfluentialPsychedelics, psychiatry and pharmacokinetics - where are we now?
Caulfield, A., Hampsey, E., & Young, A. H. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2549987 · Cited by 2 · see citing works
“…parameters, including C max (maximum plasma concentration), T max (time to peak plasma concentration), and half-life, describe the temporal dynamics of psychedelic pharmacokinetics and closely mirror the acute psychedelic experience [5,6], the quality of which correlates with clinical outcomes [7].”
Vogt, S. B., & Liechti, M. E. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.003 · Cited by 1 · see citing works
Baumann, M. H., Glatfelter, G. C., Walton, S. E., Krotulski, A. J., Witowski, C. G., & von Salm, J. L. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06879-8 · Cited by 1 · see citing works
“…evidence that DMT can be safely and effectively administered by the IN route in rats, and the plasma concentrations of DMT in rats given IN infusions are similar to those reported in humans receiving psychoactive IV doses (Strassman and Qualls 1994; Good et al. 2023; Vogt et al. 2023).”
InfluentialPerkins, D., Halman, A., Urokohara, A., Palumbo, J., Low, M., Ruffell, S., Coelho, N. L. G., Collins, L., Norman, A. F., & Sarris, J. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-25767-x · Cited by 1 · see citing works
Stocker, K., Hartmann, M., Barrett, F. S., Richards, W., Sepeda, N. D., Straumann, I., Klaiber, A., Vogt, S. B., Erne, L., Ley, L., et al. (2026) · Religion Brain & Behavior · doi:10.1080/2153599x.2026.2635353 · Cited by 1 · see citing works
Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland
Kelly, J. R., Sheridan, C., Iusan, P., Coakley, L., Burke, L., Brennan, C., MacDonald, A. A., Ivers, J., Trépel, D., Tormey, G., et al. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag028 · Cited by 1 · see citing works
Egger, K., Bozsak, R., Aicher, H., Sari, H., Poetzsch, S. N., Rominger, A., Martin-Soelch, C., Smallridge, J. W., Dornbierer, D., Quednow, B. B., et al. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261454172 · Cited by 1 · see citing works
“2 Among the classical psychedelic substances, DMT stands out due to its intense but short-acting effects when administered intravenously, 3,4 and is widely known for its traditional use in ayahuasca, a psychoactive decoction with a long history of ceremonial use among indigenous Amazonian cultures,…”
Bhat, A., Zolali, E., Sakib, M. A., Rahimian, M., McMahon, L. R., German, N., & Obeng, S. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00202 · Cited by 1 · see citing works
Postránecká, Z., Lucký, M., Mravčík, V., & Páleníček, T. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00514 · Cited by 1 · see citing works
van der Heijden, K. V., Makai‐Bölöni, S., Inamdar, A., Otto, M. E., Hegle, A. P., Aa, L., Zuiker, R. G. J. A., Bohoslavsky, R., de Kam, M. L., James, E., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261473451 · Cited by 1 · see citing works
Greene, S. L. (2025) · Comprehensive analytical chemistry · doi:10.1016/bs.coac.2024.12.002 · Cited by 1 · see citing works
Schimmelpfennig, J., & Jankowiak-Siuda, K. (2023) · Pharmacotherapy in Psychiatry and Neurology · doi:10.5114/fpn.2023.131979
Kerna, N. A., Pruitt, K. D., Carsrud, N. D. V., Kadivi, K., Ngwu, D. C., Holets, H. M., Flores, J. V., Nnake, I., Azi, C. I., Anderson, J., et al. (2024) · European Journal of Arts Humanities and Social Sciences · doi:10.59324/ejahss.2024.1(3).10
“IV doses range from 0.2 to 0.4 mg/kg, with most trials using 0.4 mg/kg as the highest dose (Vogt et al., 2023).”
BackgroundMethodInfluentialPsychosis in a Military Veteran in the Context of Hallucinogen Use: A Case Report
Parhami, P., Moriarty, S. E., Parikh, J., & Galicki, L. (2025) · Cureus · doi:10.7759/cureus.79308
“DMT has a short half-life, with plasma levels rapidly decreasing within minutes of intravenous administration, typically ranging from 5 to 15 minutes [3].”
Bahceci, D., Siefried, K. J., Steele, M., Harrod, M., Bell, G., Barratt, M. J., Nicholas, C. R. N., Rodgers, A., Hendricks, P. S., Stauffer, C. S., et al. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112699
Predicting and exploring ayahuasca effects: Perception, mind-wandering, and EEG oscillations
Silva-Costa, N., Pessoa, J. A., Andrade, K. C., Mota-Rolim, S. A., Palhano-Fontes, F., de Araújo, D. B., & Wießner, I. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251389563
“…all MEQ factors and two subfactors, corresponding to findings in inhaled DMT (Falchi-Carvalho et al., 2025; Wießner et al., 2025), intravenous DMT (Timmermann et al., 2018), continuously injected DMT (Vogt et al., 2023), and other classic psychedelics (Ley et al., 2023; Reckweg et al., 2021).”
D’Amelio, T. A., Garbagnoli, T. G., Cuello, J. R., Lewis-Healey, E., Pallavicini, C., Cavanna, F., Bruno, N. M., de la Fuente, L. A., Muller, S. A., Copa, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.30.721872
“Because the studies with which we compare our time courses administered DMT intravenously 7,26,28,31,46 , differences in the magnitude and timing of effects between those studies and ours may partly reflect the route of administration.”
InfluentialZhang, T., Lin, C., & Wang, X. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00146
Hampsey, E., Martin, K., Kalfas, M., Benson, L. E., Wihlborg, S., Jelen, L. A., Young, A. H., & Rucker, J. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453938
“…al., 2024; Lanaro et al., 2021; Ley et al., 2023; Lindenblatt et al., 1998; Mallaroni et al., 2023; Mason et al., 2020; Morse et al., 2025; Reckweg et al., 2021; Riba et al., 2003; Rucker et al., 2024; Strassman et al., 1996; Van Der Heijden et al., 2025; Viktorin et al., 2022; Vogt et al., 2023).”
The Evolution of Psychedelics and Psychedelic-Assisted Therapy
Brar, G., Lally, K., Kelly, J. R., & O'Connell, H. P. (2026) · Springer eBooks · doi:10.1007/978-3-032-27009-2_16
van der Heijden, K. V., Jacobs, G. E., James, E., Nathan, P. J., Otto, M. E., Bohoslavsky, R., de Kam, M. L., van Gerven, J. M. A., & Inamdar, A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261478616
Sawicka, G., Martínez-Marín, M., Timmermann, C., Carhart-Harris, R. L., Kringelbach, M. L., Perl, Y. S., Vohryzek, J., & Deco, G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.22.753116
Collyer, C., Le, G. H., Hassan, M., Wong, S., & McIntyre, R. S. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111966
Laborde, S., Falchi-Carvalho, M., Maia, L. O., Tullman, S., Barros, H., de Lima-Araujo, G. L., Bolcont, R., Wießner, I., Coelho, N. L. G., Palhano-Fontes, F., et al. (2026) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2026.102773
- Authors
- Vogt, S. B., Ley, L., Erne, L., Straumann, I., Becker, A. M., Klaiber, A., Holze, F., Vandersmissen, A., Mueller, L., Duthaler, U., Rudin, D., Luethi, D., Varghese, N., Eckert, A., & Liechti, M. E.
- Affiliations
- University of Basel (CH)
- Corresponding author
- Liechti, Matthias E.
- ORCID
- Venue
- Translational Psychiatry
- Published
- 2023-05-23
- Volume
- 13
- Issue
- 1
- Pages
- 172-172
- ISSN
- 2158-3188 (ISSN-L)
- PMC
- PMC10206108
- OpenAlex
- W4377940122
- Cited by
- 89
- References
- 34
- Citations by year
- 2026: 21 · 2025: 32 · 2024: 25 · 2023: 11
- FWCI
- 25.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Translational Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (32003B_185111, P5R5PM_206796)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Keywords
- N,N-dimethyltryptamine, psychedelic effects, acute tolerance, pharmacokinetics, plasma half-life, brain-derived neurotrophic factor, oxytocin, autonomic effects, adverse effects, anxiety
- MeSH terms
- Anxiety, N,N-Dimethyltryptamine, Hallucinogens, Humans, Administration, Intravenous, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
